Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

 Heidelberg, Germany, June 17, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the successful completion of the first dose cohort in a Phase 1/2a clinical trial of AFM24.

Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Affimed (AFMD) Catches Eye: Stock Jumps 7.2%

  Mr. Smith brings broad financial management and US capital markets expertise

Affimed Announces Appointment of Angus Smith as Chief Financial Officer

REDIRECT is a Registration-directed  Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

Heidelberg, Germany, May 28,  2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 8:00 a.m. Eastern Time. 

Affimed to Present at the Jefferies Virtual Healthcare Conference

Heidelberg, Germany, May 15, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK® platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held on June 22-24, 2020. Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Affimed N.V. (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy

Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2019 Results - Earnings Call Transcript

Shares of Affimed (NASDAQ:AFMD) rose 0.9% in pre-market trading after the company reported Q4 results.

Affimed: Q4 Earnings Insights

Heidelberg, Germany, April 28, 2020 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2019 and provided an update on clinical and corporate progress.

Affimed Reports 2019 Financial Results and Recent Operational Progress

Heidelberg, Germany, April 16, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the first patient was successfully dosed in a Phase 1/2a clinical trial of AFM24, a first in human study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager, is novel due to its activation of innate immunity to kill solid tumors, inducing both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as compared to other therapies that rely heavily on signal or checkpoint inhibition.

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

Heidelberg, Germany, April 1, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AFM13, its lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma. The granted designation includes peripheral T cell lymphoma (pTCL), a subtype of T-cell lymphoma. AFM13 is being investigated as a monotherapy for the treatment of relapsed or refractory CD30-positive pTCL in a Phase 2 registration-directed study.

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

Heidelberg, Germany, March 26, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company will participate in the following upcoming virtual investor conferences.

Affimed Announces Participation at Upcoming Virtual Investor Conferences

Dr. Schottelius, former executive at Kymab, MorphoSys and Genentech, brings extensive innate immunity expertise and successful record of advancing discovery research into preclinical and clinical development

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

Heidelberg, Germany, February 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 10:30 a.m. Eastern Time.

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Heidelberg, Germany, February 3, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Florian Fischer, Chief Financial Officer (CFO) of Affimed, passed away this weekend due to complications related to neoplasia.

Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer

Affimed: An Impressive Platform And An Enticing Valuation

Heidelberg, Germany, January 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020. In this role, he will oversee Affimed’s first-in-class innate cell engager clinical programs and lead the Company’s efforts to advance clinical-stage assets towards regulatory approvals.

Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer

Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition to the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 23, 2019.

Affimed Announces Addition to NASDAQ Biotechnology Index

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2019 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019.

Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates

Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 3:20 pm GMT / 10:20 am ET in London.

Affimed to Present at the Jefferies 2019 London Healthcare Conference

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

Heidelberg, Germany, November 8, 2019 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 12,000,000 of its common shares at a public offering price of $2.50 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $28.2 million. The offering is expected to close on or about November 13, 2019, subject to customary closing conditions.

News for Affimed Stock (AFMD)